Table 3

Association between hormone replace therapy and intracranial meningioma in post-menopausal women

Exposure*

Cases n

Controls n

OR (95% CI)


Hormone replacement therapy (HRT)

Never

38

58

Referent

Past

40

73

0.7 (0.4 – 1.3)

Current use on reference date

23

41

1.0 (0.4 – 2.2)

Years of HRT use

Never

38

58

Referent

Up to 5 years

28

43

0.9 (0.4 – 1.7)

More than 5 years

32

65

0.9 (0.5 – 1.7)

First HRT exposure relative to reference date

Never

38

58

Referent

1–9 years before

30

44

0.9 (0.4 – 1.9)

10 or more years before

31

62

0.9 (0.5 – 1.6)

Type of HRT preparation

None

38

58

Referent

Estrogen

33

66

0.9 (0.5 – 1.6)

Estrogen and Progestin

24

33

1.3 (0.6 – 2.8)


* Reported exposure before reference date, which for a case and her two matched controls was the date the case had surgery for her meningioma.

† Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable conditional logistic regression including continuous age and three categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. None of the tests for linear trend was significant.

Custer et al. BMC Cancer 2006 6:152   doi:10.1186/1471-2407-6-152

Open Data